NDAORALCAPSULE
Approved
Jan 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
CITALOPRAM HYDROBROMIDE (citalopram) by Almatica Pharma is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). First approved in 2022.
Drug data last refreshed 8h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Citalopram hydrobromide is an oral selective serotonin reuptake inhibitor (SSRI) approved in January 2022 for the treatment of depression. It works by inhibiting CNS neuronal reuptake of serotonin (5-HT), potentiating serotonergic activity in the central nervous system. The exact mechanism remains incompletely characterized but is presumed related to serotonin pathway modulation.
Peak
Product is in peak commercial lifecycle stage; stable to growing revenue expected with moderate competitive pressure (30% intensity) supporting sustained team sizing.
Mechanism of Action
unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study to Evaluate the Adjunctive Effect of CreNeuroS™ CNS Fish Oil Plus Softgels in Patients With Major Depressive Disorder Receiving Escitalopram.
Started Jun 2026
80 enrolled
Adjunct in the Treatment of Depressive Disorder
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Started May 2026
186 enrolled
Major Depressive DisorderMild Neurocognitive DisorderHIV
Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)
Started Mar 2021
132 enrolled
Anxiety
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
Started Oct 2020
0Major Depressive Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Started May 2019
273 enrolled
Anxiety Disorders,Generalized Anxiety Disorder
Worked on CITALOPRAM HYDROBROMIDE at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.